KLF13 is a sequence-specific DNA-binding transcription factor that regulates gene expression through binding to GC-rich promoter elements 1. Beyond its canonical transcriptional roles, KLF13 functions as a multi-pathway regulator with significant disease implications. In cancer contexts, KLF13 promotes progression across multiple malignancies: in esophageal cancer, it enhances cell proliferation and migration by activating GPIHBP1 to regulate lipid metabolism 2; in lung adenocarcinoma, it suppresses GPX4 expression to promote ferroptosis and chemosensitivity 3; in gastric cancer, it activates the NF-κB pathway to enhance migration and invasion 4; and in breast cancer, it promotes aggressiveness through HTRA1 and Hedgehog signaling 5. KLF13 also plays critical roles in viral pathogenesis and cellular homeostasis: HPV E7 protein increases KLF13 expression to facilitate productive viral replication and cervical cancer development 6, while in skeletal muscle, KLF13 restrains the Dll4-Notch2 axis to prevent dexamethasone-induced atrophy 7. Epigenetically, KLF13 methylation correlates with childhood obesity and BMI-associated traits 8, and in rheumatoid arthritis synovial tissues, KLF13 functions as a key driver in B cell regulatory networks 9. These diverse functions position KLF13 as a pleiotropic transcriptional regulator with therapeutic potential across oncology, metabolic disease, and inflammatory disorders.